Frequent methylation of Eyes absent 4 gene in Barrett's esophagus and esophageal adenocarcinoma

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 4, 2005, Pages 830-834

  Zou, Hongzhi ^a   Osborn, Neal K ^a   Harrington, Jonathan J ^a   Klatt, Kristie K ^a   Molina, Julian R ^a   Burgart, Lawrence J ^a   Ahlquist, David A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BISULFITE; MESSENGER RNA;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; DEMETHYLATION; DISEASE MARKER; ESOPHAGEAL ADENOCARCINOMA; EYES ABSENT 4 GENE; FEMALE; GENE; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METHYLATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; METHYLATION; MIDDLE AGED; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL;

EID: 16444373924     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-04-0506     Document Type: Article

References (54)

1. Bollschweiler E, Wolfgarten E, Gutschow C, Holscher AH. Demographic variations in the rising incidence of esophageal adenocarcinoma in white males. Cancer 2001;92:549-55.
2. Sharma P, Sampliner RE. The rising incidence of esophageal adenocarcinoma. Adv Intern Med 2001;46:137-53.
3. Conio M, Cameron AJ, Romero Y, et al. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut 2001;48:304-9.
4. Eloubeidi MA, Mason AC, Desmond RA, El-Serag HB. Temporal trends (1973-1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope? Am J Gastroenterol 2003;98:1627-33.
5. Jankowski JA, Wright NA, Meltzer SJ, et al. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol 1999;154:965-73.
6. Falk GW. Barrett's esophagus. Gastroenterology 2002;122:1569-91.
7. Morales CP, Souza RF, Spechler SJ. Hallmarks of cancer progression in Barrett's oesophagus. Lancet 2002;360:1587-9.
8. Dulai GS, Guha S, Kahn KL, Gornbein J, Weinstein WM. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology 2002;122:26-33.
9. Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA. Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 2002;122:633-40.
10. McManus DT, Olaru A, Meltzer SJ. Biomarkers of esophageal adenocarcinoma and Barrett's esophagus. Cancer Res 2004;64:1561-9.
11. Barrett MT, Sanchez CA, Prevo LJ, et al. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 1999;22:106-9.
12. Bian YS, Osterheld MC, Fontolliet C, Bosman FT, Benhattar J. p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus. Gastroenterology 2002;122:1113-21.
13. Wong D-J, Paulson TG, Prevo LJ, et al. p16 (INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 2001;61:8284-9.
14. Eads CA, Lord RV, Wickramasinghe K, et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 2001;61:3410-8.
15. Borsani G, DeGrandi A, Ballabio A, et al. EYA4, a novel vertebrate gene related to Drosophila eyes absent. Hum Mol Genet 1999;8:11-23.
16. Xu P-X, Adams J, Peters H, Brown MC, Heaney S, Maas R. Eya1-deficient mice lack ears and kidneys and show abnormal apoptosis of organ primordia. Nat Genet 1999;23:113-7.
17. Xu P-X, Woo I, Her H, Beier DR, Maas RL. Mouse Eya homologues of the Drosophila eyes absent gene require Pax6 for expression in lens and nasal placode. Development 1997;124:219-31.
18. Abdelhak S, Kalatzis V, Heilig R, et al. Human homologue of the Drosophila eyes absent gene underlies branchio-oto-renal (BOR) syndrome and identifies a novel gene family. Nat Genet 1997;15:157-64.
19. Abdelhak S, Kalatzis V, Heilig R, et al. Clustering of mutations responsible for branchio-oto-renal (BOR) syndrome in the eyes absent homologous region (eyaHR) of EYA1. Hum Mol Genet 1997;6:2247-55.
20. Vincent C, Kalatzis V, Abdelhak S, et al. BOR and BO syndromes are allelic defects of EYA1. Eur J Hum Genet 1997;5:242-6.
21. Wayne S, Robertson NG, DeClau F, et al. Mutations in the transcriptional activator EYA4 cause late-onset deafness at the DFNA10 locus. Hum Mol Genet 2001;10:195-200.
22. Pfister M, Toth T, Thiele H, et al. A 4-bp insertion in the eya-homologous region (eyaHR) of EYA4 causes hearing impairment in a Hungarian family linked to DFNA10. Mol Med 2002;8:607-11.
23. Maier S, Lesche R, Haefliger C, et al. Methylation profiling to identify colon cancer markers for early detection of disease. Proc Am Assoc Cancer Res 2003;44:R1131.
24. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-6.
25. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999;21:103-7.
26. Kondo Y, Shen L, Issa JP. Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol Cell Biol 2003;23:206-15.
27. Berggren P, Kumar R, Sakano S, et al. Detecting homozygous deletions in the CDKN2A (p16(INK4a))/ARF(p14(ARF)) gene in urinary bladder cancer using real-time quantitative PCR. Clin Cancer Res 2003;9:235-42.
28. Schumann H, Holtz J, Zerkowski HR, Hatzfeld M. Expression of secreted frizzled related proteins 3 and 4 in human ventricular myocardium correlates with apoptosis related gene expression. Cardiovasc Res 2000;45:720-8.
29. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28.
30. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999;21:163-7.
31. Knudson AG Jr, Hethcote HW, Brown BW. Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. Proc Natl Acad Sci U S A 1975;72:116-20.
32. Sellar GC, Watt KP, Rabiasz GJ, et al. OPMCL at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nat Genet 2003;34:337-43.
33. Clark SW, Fee BE, Cleveland JL. Misexpression of the eyes absent family triggers the apoptotic program. J Biol Chem 2002;277:3560-7.
34. Markl ID, Cheng J, Liang G, Shibata D, Laird PW, Jones PA. Global and gene-specific epigenetic patterns in human bladder cancer genomes are relatively stable in vivo and in vitro over time. Cancer Res 2001;61:5875-84.
35. Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer 2002;2:210-9.
36. Zou H-Z, Yu B-M, Wang Z-W, et al. Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin Cancer Res 2002;8:188-91.
37. Sanchez-Cespedes M, Esteller M, Wu L, et al. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 2000;60:892-5.
38. Esteller M, Sanchez-Cespedes M, Resell R, et al. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999;59:67-70.
39. Honorio S, Agathanggelou A, Schuermann M, et al. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients. Oncogene 2003;22:147-50.
40. Belinsky SA, Palmisano WA, Gilliland FD, et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 2002;62:2370-7.
41. Gilliland FD, Harms HJ, Crowell RE, Li Y-F, Willink R, Belinsky SA. Glutathione S-transferase P1 and NADPH quinone oxidoreductase polymorphisms are associated with aberrant promoter methylation of P16(INK4a) and O(6)-methylguanine-DNA methyltransferase in sputum. Cancer Res 2002;62:2248-52.
42. Chen J-T, Chen Y-C, Wang Y-C, Tseng R-C, Chen C-Y, Wang Y-C. Alterations of the p16 (ink4a) gene in resected nonsmall cell lung tumors and exfoliated cells within sputum. Int J Cancer 2002;98:724-31.
43. Palmisano WA, Divine KK, Saccomanno G, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000;60:5954-8.
44. Dulaimi E, Uzzo RG, Greenberg RE, Al-Saleem T, Cairns P. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res 2004;10:1887-93.
45. Chan M-W, Chan L-W, Tang N-L, et al. Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients. Int J Cancer 2003;104:611-6.
46. Jeronimo C, Usadel H, Henrique R, et al. Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology 2002;60:1131-5.
47. Muller HM, Oberwalder M, Fiegl H, et al. Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet 2004;363:1283-5.
48. Ahlquist DA, Klatt KK, Harrington JJ, Cunningham JM. Novel use of hypermethylated DNA markers in stool for detection of colorectal cancer: a feasibility study. Gastroenterology 2002;122:Suppl A40.
49. Molina JR, Ahlquist D. Detection of pancreatic cancer by assay of DNA alteration in stool. Gastroenterology 2004;126:Suppl A37.
50. Belshaw NJ, Elliott GO, Williams EA, et al. Use of DNA from human stools to detect CpG island methylation of genes implicated in colorectal cancer. Cancer Epidemiol Biomarkers Prev 2004;13:1495-501.
51. Lu X, Xu T, Qian J, Wen X, Wu D. Detecting K-ras and p53 gene mutation from stool and pancreatic juice for diagnosis of early pancreatic cancer. Chin Med J (Engl) 2002;115:1632-6.
52. Caldas C, Hahn SA, Hruban RH, et al. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 1994;54:3568-73.
53. Ahlquist D, Cameron A, Jett J, Pearson R. Universal detection of aerodigestive cancers by assay of nonapoptotic human DNA in stool. Gastroenterology 2002;118:Suppl A855.
54. Falk GW, Chittajallu R, Goldblum JR, et al. Surveillance of patients with Barrett's esophagus for dysplasia and cancer with balloon cytology. Gastroenterology 1997;112:1787-97.